It is well known that the envelope antigens of influenza virus, hemagglutinin (HA), and neuraminidase (NA), are strain-specific antigens and that the internal antigens of the virions, the socalled soluble (s) antigens, are type-specific (14) . As for antibodies against envelope antigens, inhibition tests for each biological activity have been employed, that is, hemagglutination inhibition (HI) and neuraminidase inhibition (NAI) tests. On the other hand, the complement fixation (CF) test is commonly employed to assay antibody against the internal virion antigens in most clinical virus laboratories (7) .
At present in Japan, split vaccine of influenza virus is given annually to school children from kindergarten to senior high school age (1) . Antibodies against both HA and NA antigens, but not against internal antigen, nucleoprotein (NP), have been reported to rise after split influenza virus vaccination (15) . While it is necessary to titrate antibody levels against s antigen to distinguish natural infection from vaccine response, the standard CF test remains less popular for serodiagnosis than the HI test because it is somewhat more complex and time consuming. In previous publications, the immuno-doublediffusion and the single radial immunodiffusion tests against NP of influenza A virus have been reported (12, 16) . Other authors have suggested modifying the principle of CF for the immunodiffusion technique, using agarose containing influenza virus s antigen, complement, sheep erythrocytes (SRBC), and hemolysin (2, 3) . In this communication we describe use of the single radial complement fixation (SRCF) test to assay influenza virus s antigen (modified by Sato et al. [10] ) as a useful and simple method for assaying complement-fixing antibodies to the type-specific antigens of influenza virus in paired human sera collected from subjects who became infected and who received vaccine. MATERIALS (Fig. 2) . The same results were also obtained when the Correlation between CF and SRCF tests. A total of 120 human sera were employed to compare SRCF units and CF titers against s antigen of influenza B virus. A good linear relationship was obtained between CF titers and SRCF units for the sera, with a correlation coefficient of 0.89 (Fig. 3) . Also, the regression line was calculated as Y = 10.4 x log(X) + 1.5, where Y is the SRCF units and X is the CF titer. On the other hand, the correlation coefficients between SRCF units and HI titers against B/Singapore/222/79 and NAI titers against B/Tohoku Univ./63/82 were 0.69 and 0.12, respectively. These results indicate that the SRCF units demonstrated were highly specific for the internal s antigen of influenza virus rather than for envelope antigens HA and NA.
Distribution of SRCF units in paired sera collected from persons with confirmed influenza infections. Fifty-seven paired sera taken from persons from whom influenza B virus was isolated and 44 paired sera taken from those yielding HlNl influenza A virus were examined by using the SRCF test against each s antigen of influenza virus. Figure 4 shows the distribution of SRCF units and CF titers in acute-and convalescent- (Fig. 4) . This trend was also observed in CF titrations. Table 2 . In influenza B virus infections, significant antibody rises against s antigen were observed with 93% of the paired sera in the SRCF test, whereas the CF test detected significant titer rises in only 86% of the subjects. Also, the HI and NAI tests revealed significant antibody rises in 79 and 68% of the subjects, respectively. All of the patients showed significant antibody rises in either SRCF tests or HI tests, or both. In influenza A virus infections, the SRCF test detected significant antibody rises in 73% of the cases. HI, NAI, and CF positive test results were 68, 71, and 64%, (a) respectively. In influenza B virus infections, the ratios of antibody levels between acute-and convalescent-phase sera titrated by SRCF ranged from 1.1 to 7.2 and the mean ratio was 2.5. The ratios ranged from 1.0 to 2.1 with a mean of 1.4 in influenza A virus infections (data not shown). It is noteworthy that the SRCF test detected the highest incidence of antibody rises in both influenza A and B infections, and that only 52% of influenza A and 58% of influenza B patients showed significant antibody rises against the full set of HA, NA, and s antigens.
SRCF antibody response after influenza virus vaccination. Figure 5 shows 
